Metsera is advancing promising obesity treatments with amylin and GLP-1 analogs, eyeing competitive efficacy and buyout ...

Metsera Inc.’s shares jumped after the obesity startup shared better-than-expected data on a weight-loss shot that would ...

Metsera (NASDAQ:MTSR) added ~16% on Tuesday as Wall Street continued to cheer early-stage trial data the company posted for ...

Metsera stock surged Monday after the drugmaker unveiled "solid" results for a potential monthly shot to stoke weight loss.

Early-stage study results suggest that a single shot of the company’s therapy, which works differently than GLP-1 medicines, ...

In what Guggenheim Partners called one of Metsera’s “critical program milestones” this year, its ultra-long-acting amylin ...

Metsera’s obesity drug candidate targeting the amylin hormone showed marked efficacy in an early trial, the company said ...

An experimental Metsera obesity drug led to an average 8.4% weight loss in a small clinical trial, preliminary results that keep the biotech competitive in the crowded mix of companies pursuing a ...

Metsera, the obesity-focused biotech, said this morning that its drug candidate targeting the amylin hormone showed marked ...

Metsera has linked its amylin analog to 8.4% placebo-adjusted weight loss at Day 36, advancing its push to develop an ...

Metsera's MET-233i shows sustained weight loss, long duration of action, and mild side effects in a Phase 1 trial, advancing its obesity treatment plans.

NEW YORK - Metsera, Inc. (Nasdaq: MTSR), a clinical-stage biopharmaceutical company valued at $2.89 billion, today revealed positive topline results from its Phase 1 clinical trial for MET-233i ...